The endocannabinoid system in migraine from bench to pharmacy and backTassorelli, Cristinaa,b; Greco, Rosariaa; Silberstein, Stephen D.cCurrent Opinion in Neurology: June 2019 - Volume 32 - Issue 3 - p 405–412 doi: 10.1097/WCO.0000000000000688 HEADACHE: Edited by Messoud Ashina and Henrik Winther Schytz Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Migraine is a common, highly disabling disorder. Its treatment involves acute and preventive therapy. Many of available preventive medications are not well tolerated, which results in poor compliance and limited effectiveness. Cannabinoids have been proposed for the treatment of migraine but their efficacy and tolerability are controversial. Recent findings Cannabinoids modulate functions and activity of signaling pathways that have a key role in pain control. Growing preclinical evidence and initial clinical findings suggest that modulation of the endocannabinoid system, via endogenous or exogenous cannabinoids may be relevant for migraine via multiple mechanisms. Summary The endocannabinoid system qualifies as an interesting area of research worth exploration in the quest for therapeutic targets for the treatment of migraine. aHeadache Science Center, IRCCS Mondino Foundation bDepartment of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy cJefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Correspondence to Cristina Tassorelli, MD, PhD, IRCCS C. Mondino Foundation, Via Mondino 2, 27100 Pavia, Italy. Tel: +39 0382380419; fax: +39 0382380448; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights resereved.